Health-related quality of life in patients with indolent and aggressive non-Hodgkin lymphoma

نویسندگان

  • Eliza M. Alawi
  • Krystyna A. Mathiak
  • Jens Panse
  • Klaus Mathiak
چکیده

Indolent and aggressive non-Hodgkin lymphomas (NHL) are common types of hematologic malignancies but their effect on quality of life (QoL) is understudied. In particular, the relation between different aspects of QoL and cognitive impairments and coping styles is relevant for individualized physical and mental health care. We studied emotional, physical, and subjective well-being in relation to cognitive capacities and coping style in 100 patients with NHL (44 females, age 61.3 ± 13.6). Questionnaires assessed health-related QoL (Functional Assessment of Cancer Therapy (FACT)), affect (Hospital Anxiety and Depression Scale, Positive and Negative Affective Schedule), distress (Distress Thermometer), and locus of control; semi-structured interviews targeted subjective QoL (Schedule for Evaluating the Individual Quality of Life) and cognitive impairments (Test for Early Detection of Dementia with Differentiation from Depression). Indolent NHL (n = 44) yielded better health-related QOL and positive affect and less anxiety than the aggressive type (n = 55; FACT: t(97) = 1.90, p = .028, anxiety: t(97) = −1.9, p = .030; positive affect: t(96) = 2.01, p = .023). In a factor analysis, physical and affective scales loaded on an emotional and physical well-being factor, which differed between the groups. Further, cognitive capacities and locus of control contributed to subjective QoL and reported distress. Emotional and physical scales assess QoL in NHL. However, *Corresponding author: Klaus Mathiak, Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital Aachen, RWTH Aachen University, Pauwelsstr. 30, Aachen 52074, Germany E-mail: [email protected]

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Eye Lymphoma: a Case Report

Non Hodgkin Lymphomas (NHL) are nodal or extra nodal monoclonal infiltrations by malignant lymphoid cells (B Lymphocytes in 80% of cases), which are distinguished as indolent or aggressive forms. According to the heterogeneity of lymphoid cells and their ubiquitous anatomical distribution, these disorders can develop in any organ and have very heterogeneous clinical expressions, but they are...

متن کامل

Non-hodgkin Lymphoma

Non-Hodgkin ́s lymphoma is very diverse and includes over 60 specific lymphoma types. They are grouped by their aggressiveness. Some of them grow and spread slowly, and are called indolent lymphomas. These lymphomas are less lifethreatening, but they are much harder to cure definitively. Other lymphomas tend to grow more rapidly and aggressively and spread quickly through the body. They can even...

متن کامل

گزارش یک مورد لنفوم غیر هوچکین در حفره دهان

Malignant lymphoma is the neoplastic transformation of Cells, mostly originating from lymphoid tissues. Malignant lymphoma has two major subtypes: Hodgkin and non-Hodgkin lymphoma. Malignant lymphoma is the most common neoplasm in 3rd and 4th decades of life and more than two third of affected patients presented painless peripheral lymphadenopathy. Involvement of waldeyer’s ring, epitrochlear a...

متن کامل

Allogeneic transplantation in lymphoma: current status.

Allogeneic transplantation of hematopoietic stem cells (allo-SCT) is being increasingly used to treat patients with lymphoma. We describe current results of allo-SCT in patients with Hodgkin's disease, indolent lymphoma including Waldenström's disease, and aggressive lymphoma including mantle cell lymphoma and mature T-cell lymphomas. A Graft-vs.-Lymphoma (GvL) effect is present in most entitie...

متن کامل

Radioimmunotherapy for B-cell non-hodgkin lymphomas.

BACKGROUND Radioimmunotherapy (RIT) is a safe and effective therapeutic option for patients with indolent B-cell non-Hodgkin lymphomas (NHL), in both up-front and relapsed/refractory settings. Two approved agents (90Y-ibritumomab tiuxetan and 131I-tositumomab) are available in the United States. Both target CD20 with similar clinical outcomes but with unique clinical considerations and radiatio...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2016